trending Market Intelligence /marketintelligence/en/news-insights/trending/MXlAtyOhCLuMHkyMeXi6rQ2 content esgSubNav
In This List

Aytu BioScience launches $10M private placement


Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback


Infographic: The Big Picture 2023 Sustainability Outlook


The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism

Aytu BioScience launches $10M private placement

Aytu BioScience Inc. is raising $10 million in a private placement of its series F convertible preferred stock and warrants to buy common stock.

Institutional investors Altium Capital and Armistice Capital jointly participated in the deal.

The shares of preferred stock will be sold at $1,000 per share and are convertible into 1,000 common shares at $1 per share. The preferred shares are also accompanied by warrants to buy up to one common share for each share of common stock convertible from the preferred stock, exercisable at $1.25 per share.

The five-year warrants are exercisable following shareholder approval.

Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent in connection with the offering.

Englewood, Colo.-based Aytu Bioscience develops products for hypogonadism, insomnia and male infertility. The company recently agreed to acquire a portfolio of six prescription products from Cerecor Inc. for an up-front payment of $17 million.